Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05811364 · ClinicalTrials.gov registry record · NA
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
A NA study of Peripheral Arterial Disease and Aortoiliac Occlusive Disease, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- NA
- Development phase
- 244
- Enrollment target
- 7
- Study locations
NCT05811364 is a NA study of Peripheral Arterial Disease and Aortoiliac Occlusive Disease that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 244 participants, below the 4,203-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05811364, a NA study of Peripheral Arterial Disease and Aortoiliac Occlusive Disease, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- NA
- Development phase
- 244 participants
- Enrollment target
- 7
- Study locations
Study Summary
The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.
Conditions Studied
Interventions
- DEVICE Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
- DEVICE Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Study Locations (7)
Other
- Krankenhaus der Barmherzigen Brüder - Regensburg
- Rijnstate Hospital - Arnhem
- Auckland City Hospital - Auckland
Colorado
- North Suburban Medical Center - Denver
Florida
- Radiology and Imaging Specialists of Lakeland - Lakeland
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2032-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05811364
The ClinicalTrials.gov registry entry for NCT05811364 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,203-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (94% lower). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is the first listed.
NCT05811364 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05811364 about?
NCT05811364 is a clinical study titled "The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease". The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.
What is the current status of trial NCT05811364?
This trial is currently recruiting. It is a NA study. The enrollment target is 244 participants. The study started on 2023-10-17. Estimated completion is 2032-01-31.
What conditions does trial NCT05811364 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Aortoiliac Occlusive Disease.
What interventions are being tested in trial NCT05811364?
The interventions under investigation include: Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (DEVICE), Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent (DEVICE).
Who is sponsoring clinical trial NCT05811364?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05811364 being conducted?
This trial has 7 study locations across Colorado, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.